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Zeta-chain-associated protein kinase-70 (ZAP-70) is a tyrosine kinase mainly expressed
in T cells, NK cells and a subset of B cells. Primarily it functions in T cell receptor (TCR)
activation through its tyrosine kinase activity. Aberrant expression of ZAP-70 has been
evidenced in different B cell malignancies, with high expression of ZAP-70 in a subset
of patients with Chronic Lymphocytic Leukemia (CLL), associating with unfavorable
disease outcomes. Previous studies to understand the mechanisms underlying this
correlation have been focused on tumor intrinsic mechanisms, including the activation of
B cell receptor (BCR) signaling. Recent evidence also suggests that ZAP-70, intrinsically
expressed in tumor cells, can modulate the cross-talk between malignant B cells and
the immune environment, implying a more complex role of ZAP-70 in the pathogenesis
of B cell malignancies. Meanwhile, the indispensible roles of ZAP-70 in T cell and NK cell
activation also demonstrate that the autologous expression of ZAP-70 in the immune
environment can be a central target in modulation of tumor immunity. Here we review the
evidences of the link between ZAP-70 and tumor immunology in the microenvironment in
B cell malignancies. Considering an emerging role of immunotherapies in treating these
conditions, understanding the distinct molecular functions of ZAP-70 in a broader cellular
context could ultimately benefit patient care.
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INTRODUCTION
Zeta-chain-associated protein kinase-70 (ZAP-70) is a tyrosine kinase mainly expressed in T cells
and NK cells (1, 2). The function of ZAP-70 in T cell receptor (TCR) activation through its
tyrosine kinase activity has been well-studied through pioneering works by the Weiss laboratory
and others [for review see (3)]. In the early 2000s, the aberrant high expression of ZAP-
70 was identified in a subset of Chronic Lymphocytic Leukemia (CLL) patients (4), which
turned out to also reflect an unfavorable clinical outcome (5). Much work has been done to
establish ZAP-70 as a prognostic marker in CLL, assuming that assessment of its expression
was somehow less time and labor-consuming than IGHV mutation analyses (6). However, the
variation of expression levels and the lack of harmonized tests have hampered this development
(7), consequently ZAP-70 expression is not routinely assessed to guide clinical decisions.
Subsequent studies further revealed the expression of ZAP-70 in other B cell malignancies,
such as Acute Lymphoblastic Leukemia (ALL), Burkitt-lymphoma and Mantle Cell Lymphoma
(MCL) (8, 9). Although studies have shown the involvement of ZAP-70 in IgM-mediated B cell
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receptor (BCR) signaling in CLL, the role of ZAP-70 in the
pathogenesis of CLL and other B cell malignancies is still
arguable. Recently studies have implied that tumor intrinsic ZAP-
70 expression modulates the cross-talk between malignant B cells
and their environment, suggesting a new angle to understand the
role of ZAP-70 in these diseases.We will review here how ZAP-70
expression in malignant B cells has an impact on cell migration,
innate immune response, and T cell infiltration. In contrast, its
expression in T cells and NK cells can affect tumor immune
responses. Therefore, targeting ZAP-70 may exert anti-tumor
effects not only through the modulation of signaling cascades in
malignant B cells, but also through inhibition of cells resident or
recruited to the tumor microenvironment.
ZAP-70 EXPRESSION IN B CELL
MALIGNANCIES
The expression of ZAP-70 in B cell malignancies was first
detected in CLL with 20–80% of leukemic B cells having ZAP-70
expression levels equivalent to autologous CD3+ T cells in
patients, correlating with unmutated IGHV gene and poor
clinical outcomes (5, 6, 10, 11). Notably, the expression of
ZAP-70 in CLL cells frequently varies across the entire clone and
a somewhat arbitrary threshold of >20% is required to classify
a patient by flow-cytometry as “ZAP-70-positive.” Importantly,
the expression levels of ZAP-70 in CLL cells are relatively stable
over time (6, 10, 12). The aberrant ZAP-70 expression has
further been found to associate with sIgM expression in CLL
(13), which further suggested an essential role of ZAP-70 in CLL
pathogenesis and progression. Importantly, discordant cases
of ZAP-70 expression in IGHV- mutated CLL indicated that it
possesses a higher predictive value for a poor clinical outcome
and therefore strongly suggest that it may actively contribute
to the pathogenesis (5, 6). In addition to CLL, ZAP-70 is also
expressed in a fraction of B-ALL cases, including most of the
childhood pre-B cells ALL (14, 15) and adult ALL cases with
different maturation phenotypes (9, 16). Notably, ZAP-70 level
in ALL is associated with CD38 expression, but no correlation
was observed to specific cytogenetic abnormalities (9, 17).
Moreover, ZAP-70 expression was identified in a subset of
other B cell malignancies, including, Follicular Lymphoma (FL),
Mantle Cell Lymphoma (MCL), Hairy Cell Leukemia (HCL),
and Diffuse Large B-cell Lymphoma (DLBCL) by western
blotting, flow cytometry (14) and immunohistochemistry
assessment (8), and in very rare cases of classic Hodgkin
lymphoma (18).
The presence of ZAP-70 in subsets of B cell malignancies
also with immature phenotypes may reflect their cellular origin,
since ZAP-70 expression is also evidenced in normal B cells,
especially developing and differentiating B cells. Using a ZAP-70
deficient mouse model, the protein was found to be expressed
in pro-B and pre-B cells and to play a role in the process of
pro-B to pre-B cells transition in the bone marrow through
engaging in the pre-BCR complex formation (19). Notably, ZAP-
70 and SYK were functionally redundant in B cell development,
since only mice with both ZAP-70 and SYK deficiency displayed
a complete B cell developmental block (19, 20). This finding
was further supported by a study analyzing B cell populations
from human bone marrow, peripheral blood, and tonsils, which
found ZAP-70 expression in pro-B and pre-B cells but not in
the majority of normal mature B cells (9). Notably, similar
to malignant B cells, ZAP-70 expression in normal B cell
populations is also modulated by phosphorylation upon BCR
activation (14, 21).
Since ZAP-70 is normally not expressed in mature B cells, its
expression in CLL and other mature B cell-derived neoplasms
likely points to their different cellular origin (9, 15). Interestingly,
point mutations in ZAP-70, which can result in the lack of ZAP-
70 protein expression in human T cells, were not identified
in normal human B cells and ZAP-70 negative malignant B
cells (9). Therefore, the down-regulation of ZAP-70 through B
cell development may represent a physiological process of B
cell maturation.
The aberrant high ZAP-70 expression found in some mature
B cell malignancies may be caused by epigenetic modulation
and clonal evolution during tumor transformation. In CLL,
hypomethylation on CpG sites in the ZAP-70 gene 5′ regulatory
regions have been identified to be associated with high ZAP-70
expression and predictive of a poor disease outcome (22–24).
Alternative mechanisms leading to the aberrant expression of
ZAP-70 relate to tumor-microenvironment mediated induction
of ZAP-70: In B cells derived from peripheral blood, which have
consistently low ZAP-70 levels, BCR-activating stimuli (e.g., anti-
IgM, sCD40L, IL-4, IL-6, and IL-10) upregulate the expression of
ZAP-70 (14). Unmethylated CpG oligodeoxynucleotides, which
can trigger an innate immune response through TLR9 activation,
promote proliferation in a subset of CLL cells, accompanied by
ZAP-70 induction (25, 26).
TUMOR ZAP-70 EXPRESSION
MODULATES THE TUMOR- AND IMMUNE
MICROENVIRONMENT
Efforts have been made to understand the molecular role
of tumor-intrinsic ZAP-70 expression in B cell malignancies.
In CLL, ZAP-70 expression is associated with enhanced
BCR signaling upon IgM activation, evidenced by a positive
correlation between ZAP-70 expression, phosphorylation of SYK,
BLNK, and PLCγ2 and calcium response (4, 27). Notably, the
kinase activity of ZAP-70 is dispensable for BCR signaling
in CLL, since the phosphorylation of ZAP-70 catalytic sites
appears negligible compared to that of SYK (28). In addition
an introduced mutation abrogating kinase activity of the ZAP-
70 catalytic site had no significant effect on IgM-mediated BCR
signaling activation (29). This suggests that the role of ZAP-
70 in B cell malignancies is different from that in T cells.
Interestingly, despite the dispensable nature of its kinase activity,
ectopic expression of ZAP-70 in the Burkitt lymphoma line
BJAB enhanced the phosphorylation and activation of BCR-
related signaling cascades under conditions of IgM activation
(28). These findings have led to the suggestion that ZAP-70 acts
mainly as an adaptor protein to recruit downstream protein
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FIGURE 1 | Tumor expression of ZAP-70 modulates the immune microenvironment, and the functional roles of ZAP-70 in environmental T cells. In Chronic
Lymphocytic Leukemia (CLL) cells, ZAP-70 mediates BCR signal transduction through its kinase activity or as a scaffold protein recruiting other tyrosine kinases. In
addition, ZAP-70 modulates the communication between malignant cells and their tumor microenvironment. (1) ZAP-70 is involved in the regulation of CCR7, CXCR4
expression on CLL cells, which promote the migration of tumor cells toward an environment niche, secreting CCL19, CCL21, and CXCL12; (2) ZAP-70 in CLL is
engaged in TLR9 activation-mediated anti-apoptotic effects and cell proliferation, likely through mediating SYK activation and IgM secretion; (3) ZAP-70 expression in
CLL cells is associated with high levels of CCL3 and CCL4 secretion, which engage in the recruitment of T cells. In T cells in the tumor microenvironment, (4) ZAP-70
expression and phosphorylation is essential for TCR-mediated T cell activation; (5) CTLA-4 is a negative regulator of ZAP-70 phosphorylation, thus suppressing T cell
activation; (6) ZAP-70 expression in CAR-T cells is important for cell proliferation and antigen recognition. This Figure has been created with Biorender.com.
kinases, such as PI3K, c-Cbl, Cbl-b, and Shc (28). In contrast,
in B-ALL, ZAP-70 is constitutively phosphorylated, suggesting
the tyrosine kinase activity is continuously involved in ALL
biology (16). However, the detailed role of ZAP-70 in B-ALL is
still unknown.
In addition to engaging in tumor cell intrinsic signaling, likely
improving the cellular fitness of tumor cells, evidence suggest
that ZAP-70 expression is also involved in the cross-talk between
malignant B cells and their microenvironment (Figure 1).
Cell Migration
C-C chemokine receptor type 7 (CCR7) and C-X-C chemokine
receptor type 4 (CXCR4) expression on B cells is essential for
cell migration and homing during B cell development through
the binding to their putative chemokine ligands CCL19/CCL21
and CXCL12, respectively (30). High receptor expression on
malignant B cells correlates with advanced disease stage in CLL
(31), and in Diffuse Large B cell Lymphoma (DLBCL), associated
with increased bone marrow infiltration and poor outcomes
(32). Other studies have shown ZAP-70 expression correlates
with enhanced T- and B cells migration and chemotaxis in the
microenvironment. In a recent study deciphering the molecular
cues which modulate inflammation-dependent oligomerization
of the chemokine receptor CCR7 in dendritic- and T cells,
ZAP-70 has been identified as an interactor of CCR7 under
chemokine stimulation, suggesting a role of ZAP-70 in CCR7
related cell migration and chemotaxis (33). This finding is
consistent with previous studies showing ZAP-70 expression in
CLL cells correlates with CCR7 expression, induced by IgM-
mediated ERK activation, thus enhancing the migratory ability to
CCL19 and CCL21 (34, 35). A recent study has further evidenced
this in CLL patients, and observed that ZAP-70 positive CLL cells
migrated more to CCL19, CCL21, and CXCL12 by controlling
the chemokine-driven clustering of the integrins VLA-4 and
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LFA-1 (36). Moreover, ZAP-70 expression also correlates with
CCR7/CXCR4 expression in B cell precursor ALL disease and
here promotes migration toward CCL19/CXCL12 in the central
nervous system (37).
Innate Immune Responses
Besides BCRmediated signals, Toll-like receptor (TLR) signaling,
which can bridge innate and adaptive immune responses, has
been found to play a role in CLL activation and proliferation
(38, 39). Interestingly, ZAP-70 appears to play a role to
determine the environmental triggered TLR response in CLL:
A recent study from our lab has elucidated that expression
of ZAP-70 in CLL is strongly predictive of TLR9 agonists-
mediated anti-apoptotic effects and cell proliferation, likely
through mediating SYK activation, IgM secretion and Bim
degradation (26).
T Cell Infiltration
Mounting evidence indicates that the ZAP-70 expressed in tumor
cells has ramifications for the composition of immune cells in
the microenvironment, especially for the number of infiltrating
T cells. In studies comparing the immune-phenotype of ZAP-
70 positive and ZAP-70 negative CLL patients, tumor ZAP-70
expression was associated with increased CD4 central memory
T cells and CD3/CD69+ T cells with decreased CD4/CD8 ratio
in the peripheral blood (40–42). However, since high ZAP-70
expression is normally observed in only a subpopulation of
CLL cells and varies substantially between patients, it is possible
that subtle changes in different T cell populations between
ZAP-70 positive and negative patients are partly impacted by
inconsistencies in the definition of ZAP-70 positive in these
studies. Interestingly, studies have evidenced that CLL cells
secrete the C-C motif chemokine ligands, CCL3 and CCL4,
which enable the recruitment of T cells and monocytes, under
the stimulation of IgM and in co-culture with nurse-like cells
(NLC) (43). In addition, in CLL, ZAP-70 positive patients have
significantly higher CCL3 and CCL4 plasma levels (43), and
CCL3 plasma levels correlate with other risk factors (44). These
findings suggest a potential role of tumor autologous ZAP-70,
mediating immune-responses and fostering a tumor-supportive
microenvironment through modulation of the expression of T
cell chemokines.
ZAP-70 EXPRESSION IN T CELLS AND NK
CELLS, AND THEIR ROLES IN B CELL
MALIGNANCIES
Immunotherapy, including checkpoint blockade inhibition and
cell-based immunotherapies, is a fast developing area in cancer
treatment. Such treatment modalities have been applied to
treat B cell malignancies and demonstrated significant improved
outcomes in smaller subsets of patients, who previously
relapsed from chemotherapies and targeted therapies (45).
Notably, despite showing some promising effects, the molecular
mechanisms that inhibit T cell and NK cell activation in B cell
FIGURE 2 | The roles of ZAP-70 in homeostasis and cancer. The schematic
shows ZAP-70 involvement in physiological contexts and in cancer. This Figure
has been created with Biorender.com.
malignancies and block anti-tumor immunity are far from being
comprehensively described.
Because of its indispensible role for TCR activation,
deficiency, or aberrantly high expression of ZAP-70 in T
cells expectedly result in immune deficiency [ZAP-70-related
severe combined immunodeficiency syndromes (SCID)] (46)
and autoimmunity, respectively (47). To date, it remains an
important but unanswered question whether ZAP-70 expression
levels in T and NK cells are associated with patient responses to
immunotherapies, but an increasing amount of evidence suggests
that ZAP-70 deficiency or inhibition can contribute to impaired
tumor-surveillance (Figure 2).
T Cells
Structurally, ZAP-70 has been found to play a central role in
immunological synapse formation in cytotoxic T lymphocytes
(CTL) (48). CTLA-4 is a well-established inhibitory checkpoint
for T cell activation (49). It has been suggested that the inhibition
of ZAP-70 tyrosine-phosphorylation is a mechanism of CTLA-4
mediated suppression of CD4+ T activation, indicating a central
role of ZAP-70 kinase activity in T cell activation and anti-tumor
immune responses (50). In a recent study the GTPase-activating
protein (GAP) Rasal1, which inhibits ZAP-70, has been identified
to suppress anti-tumor immune-responses. Antagonizing ZAP-
70 inhibition by siRNA against Rasal1 increased the number
of CD8+ tumor-infiltrating T-cells expressing granzyme B
and interferon gamma (no ‘1’) and enhanced tumor killing
(51). Notably, in a DLBCL case, ZAP-70 deficiency caused
complete ablation of the CD8 population in the tumor
environment (52), suggesting a profound effect of ZAP-70 in
tumor immune-responses.
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NK Cells
Recently, NK cells have been applied for cancer-
immunotherapies, benefitting from its antigen-independent
host immune responses and cytotoxicity against malignant
cells (53). ZAP-70 is a kinase that is also involved in the
activation of NK cells upon engaging with ligands on targeted
cells (54) and downregulation of ZAP-70 is associated with
inhibition of NK cell responses under prolonged activation
and continuous DNA damage stress (55). A very recent study
revealed that ZAP-70 is engaged in immunomodulatory drug
pomalidomide induced granzyme-B secretion and cytolytic
activity of NK cells (56). However, ZAP-70-independent
pathways exist which modulate NK cell mediated cytotoxicity,
primarily through signaling modulated by non-ITAM-based
receptors, like NKG2D (57). It has also been described that
NK cells from SYK−/− ZAP-70−/− mice still maintain natural
cytotoxicity, which suggests a redundant role of ZAP-70 in
this process, despite driving the activation of NK cell receptor
signaling (58).
CAR-T Cells
Chimeric antigen receptor T cells (CAR-T) are T cells expressing
artificial T cell receptors which contain both tumor specific-
as well as T cell activating motifs (59). Promising results from
clinical trials had led to several CAR-T cell therapies approved by
the United States Food and Drug Administration and European
Medicines Agency for treating relapsed or refractory B cell
malignancies (60). In spite of the similarity between chimeric
antigen receptors (CARs) and natural TCRs, reduced efficiency
of antigen-recognition and affinity remainmajor issues in CAR-T
cell therapies. Third generation CAR-T cells are potentially more
efficient than second generation through engaging additional
co-stimulatory molecules. Evidence from a comparative study
indicates that activation and phosphorylation of ZAP-70 in
CAR-T cells is associated with enhanced cell proliferation and
expansion of third generation CARs, containing both CD28 and
4-1BB motifs, compared to second generation CARs (61). The
importance of ZAP-70 in CAR-T activation has been further
addressed by a very recent study: Using quantitative single-
molecule live-cell imaging, CAR-T cells have been shown to
have ∼1,000 times reduced antigen sensitivity compared to
normal T cells, and data suggest that the underlying mechanism
relates to reduced recruitment of ZAP-70 to CARs. This study
enlightens the importance of ZAP-70 in CAR-T activation and
suggests it as a promising target for improving CAR-T antigen
recognition (62).
ZAP-70 AS THERAPEUTIC TARGET
Considering the importance of ZAP-70 in T cell and NK
cell activation, great effort has been put to target ZAP-70 in
order to control diseases derived from abnormal T or NK
cell activation, such as immune disorders and autoimmune
diseases (3, 63). ZAP-70 has been found not only to function
through its kinase activity, but also as an important scaffold
protein to associate with TCR or BCR related molecules,
independent of its catalytic activity (28, 64), suggesting that
kinase-inhibition may not completely abolish protein function.
Several in vitro studies have previously investigated inhibitors
which can suppress ZAP-70 kinase activity or disrupt its protein-
binding ability to access downstream TCR related activators
(65, 66). These inhibitors have been well-described in a recent
review (63).
Although the expression of ZAP-70 in tumor cells has been
linked to a dismal outcome, there have only been few attempts
to inhibit ZAP-70 as a treatment, partly because the biological
functions of ZAP-70 in B cell malignancies remain elusive.
Tyrosine kinase inhibitors have been assessed to treat ZAP-70
positive CLL, for example, gefitinib has been tested for inducing
apoptosis of ZAP-70 positive CLL cells and cell lines in vitro.
These studies demonstrated that gefitinib inhibits the basal and
BCR activation-mediated phosphorylation of ZAP-70 at the
micromolar level and that ZAP-70 expression sensitizes cells
to gefitinib induced cell apoptosis (67). However, it is arguable
whether these pro-apoptotic effects of gefitinib were achieved
through the inhibition of ZAP-70 or other related tyrosine
kinases, such as SYK.
While ZAP-70 constitutes an interesting and attractive target
for therapeutic interventions in cancer patients, especially in
those with aberrant expression in B cell malignancies, the
simultaneous inhibition of T and NK cells appears to be
inevitable and may be less desirable and potentially even
harmful. While T cell subsets may promote tumorigenesis (e.g.,
through CD40 stimulation) and their inhibition may therefore
be therapeutically beneficial, blockage of cytotoxic T cells and
NK cells may be less so. Whether different immune cells display
different susceptibilities to ZAP-70 inhibition, thus allowing for a
wide-enough therapeutic window of antagonists to be beneficial,
is unknown, but at least seems possible. We believe this is a
substantial problem to be considered in the design of ZAP-70
directed therapies.
Immunotherapies, including CAR-T cells, immune
checkpoint blockade, and adaptive T cell therapies, have
been applied in clinical treatment for B cell malignancies. The
safe and precise control of over-reactions of anti-tumor immune
responses has been a major issue for the toxicity of cell-based
immunotherapies (68). Based on the essential role of ZAP-70 in
TCR activation, some studies suggest targeting ZAP-70 in order
to control effector T cells, which could potentially be applied for
developing safer adaptive T cell therapies (Figure 1). A recent
study defined ZAP-70 as a target to control the toxicity caused
by over-reacting CAR-T cells such as cytokine release syndrome
(CRS). Dasatinib, a tyrosine kinase inhibitor has been found
to attenuate CAR-T toxicity by suppressing ZAP-70 activation
(69). However, inhibition of other kinases by dasatinib, such
as Abl and Src tyrosine kinases, may likely contribute. An
engineered ZAP-70 construct has been established by the
Weiss lab to specifically study the role and requirement of
ZAP-70 kinase activity in different biological processes. The
so-called analog-sensitive ZAP-70 mutant (ZAP-70 AS), which
contains an engineered binding pocket around the kinase
domain, sensitive to an analog of the small molecule kinase
inhibitor PP1, conserves the normal ZAP-70 catalytic activity
and can be specifically inhibited (70). This specificity has a great
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TABLE 1 | Cell-type specific functions of ZAP-70 in B cell malignancies.
Cell types Proposed functions
Malignant B cells CLL ✧ ZAP-70 enhances BCR signaling upon IgM activation;
✧ Interactions with BCR-related proteins;
✧ ZAP-70 correlates with CCR7, CXCR4 expression and enhanced cell migration;
✧ Modulation of TLR-induced response through mediating SYK activation, IgM secretion, and
Bim degradation;
✧ Associates with CCL3 and CCL4 secretion and T cell infiltration in the tumor microenvironment.
ALL ✧ Constitutively phosphorylated, detailed role of ZAP-70 in ALL is unknown.
Others ✧ Undefined
Tumor-environment immune cells T cells ✧ Essential for TCR activation through its tyrosine kinase activity;
✧ Plays central role in immunological synapse formation in CTL.
✧ CTLA-4 in CD4+ T cells inhibits ZAP-70 activity.
NK cells ✧ NK cell activation upon receptor engagement;
✧ May be redundant in NK cell mediated cytotoxicity.
Immunotherapy CAR-T cells ✧ Associates with enhanced cell proliferation and expansion in the 3rd generation CAR-T cells contacting
both CD28 and 4-1BB;
✧ Reduced recruitment of ZAP-70 to CARs is associated with less antigen sensitivity compared to
normal T cells.
potential to be applied for the safe control of adaptive cell-based
immunotherapies (71).
CONCLUSION
ZAP-70 is not only critical for T cell and NK cell activation,
but also associated with poor outcomes of B cell malignancies,
especially in CLL. Tumor intrinsic expression of ZAP-70 in B cell
malignancies has been shown to enhance cellular signals under
ligand stimulated BCR activation. However, the underlying
mechanisms known so far cannot fully explain the correlation
between ZAP-70 expression and dismal outcome. More evidence
has pointed to ZAP-70 driven environmental changes, whichmay
play a central role for triggering innate immune responses and
immune cell infiltration (Figure 1 and Table 1).
Growing evidence also indicates that the modulation of ZAP-
70 activity can be applied to control T cell activation, which has
translational potential to mitigate the toxicity associated with
cell-based immunotherapies (Figure 1). However, since most of
the evidence has only been compiled from in vitro experiments,
more in vivo studies are needed to fully characterize whether such
therapies can be applied in a clinical setting.
A thorough review of the published evidences focusing on
defining the role of ZAP-70 in health and disease clearly indicates
that it remains an attractive target for therapeutic interventions,
more than ever. More experimental evidence is needed to fully
understand the biology behind ZAP-70 in B cell malignances
in a holistic cellular approach. The simultaneous targeting of
ZAP-70 in tumor cells, T and NK cells, may be beneficial in
some instances, but also bears the risk to promote tumor growth
through impairing immune surveillance.
AUTHOR CONTRIBUTIONS
JC and IR designed and wrote this review. AM provided
critical editing on the manuscript and the graphs. All authors
contributed to the article and approved the submitted version.
FUNDING
This work was funded by Cancer Research UK (CRUK;
C49940/A17480). IR is a senior CRUK fellow. JC is funded by
the Kay Kendall Foundation (KKLF) (KKL1070).
ACKNOWLEDGMENTS
Wewould like to thank Esther Baena for supporting the graphical
design of Figure 2.
REFERENCES
1. Brumbaugh KM, Binstadt BA, Billadeau DD, Schoon RA, Dick CJ,
Ten RM, et al. Functional role for Syk tyrosine kinase in natural
killer cell-mediated natural cytotoxicity. J Exp Med. (1997) 186:1965–74.
doi: 10.1084/jem.186.12.1965
2. Chan AC, Irving BA, Fraser JD, Weiss A. The zeta chain is associated with a
tyrosine kinase and upon T-cell antigen receptor stimulation associates with
ZAP-70, a 70-kDa tyrosine phosphoprotein. Proc Natl Acad Sci USA. (1991)
88:9166–70. doi: 10.1073/pnas.88.20.9166
3. Au-Yeung BB, Shah NH, Shen L, Weiss A. ZAP-70 in signaling,
biology, and disease. Annu Rev Immunol. (2018) 36:127–56.
doi: 10.1146/annurev-immunol-042617-053335
4. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, et al.
Expression of ZAP-70 is associated with increased B-cell receptor
signaling in chronic lymphocytic leukemia. Blood. (2002) 100:4609–14.
doi: 10.1182/blood-2002-06-1683
5. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson
SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia
subtype with unmutated immunoglobulin genes, inferior clinical
Frontiers in Oncology | www.frontiersin.org 6 October 2020 | Volume 10 | Article 595832
Chen et al. Immune-Regulation Through ZAP-70
outcome, and distinct gene expression profile. Blood. (2003) 101:4944–51.
doi: 10.1182/blood-2002-10-3306
6. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, et al. ZAP-
70 compared with immunoglobulin heavy-chain gene mutation status as a
predictor of disease progression in chronic lymphocytic leukemia. N Engl J
Med. (2004) 351:893–901. doi: 10.1056/NEJMoa040857
7. Vroblova V, Smolej L, Krejsek J. Pitfalls and limitations of ZAP-70
detection in chronic lymphocytic leukemia. Hematology. (2012) 17:268–74.
doi: 10.1179/1607845412Y.0000000015
8. Carreras J, Villamor N, Colomo L, Moreno C, Ramon y Cajal S,
Crespo M, et al. Immunohistochemical analysis of ZAP-70 expression
in B-cell lymphoid neoplasms. J Pathol. (2005) 205:507–13. doi: 10.1002
/path.1727
9. Crespo M, Villamor N, Gine E, Muntanola A, Colomer D, Marafioti T,
et al. ZAP-70 expression in normal pro/pre B cells, mature B cells, and
in B-cell acute lymphoblastic leukemia. Clin Cancer Res. (2006) 12:726–34.
doi: 10.1158/1078-0432.CCR-05-1531
10. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M,
et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region
mutations in chronic lymphocytic leukemia. N Engl J Med. (2003) 348:1764–
75. doi: 10.1056/NEJMoa023143
11. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW,
et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.
Lancet. (2004) 363:105–11. doi: 10.1016/S0140-6736(03)15260-9
12. Durig J, Nuckel H, CremerM, Fuhrer A, Halfmeyer K, Fandrey J, et al. ZAP-70
expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia.
(2003) 17:2426–34. doi: 10.1038/sj.leu.2403147
13. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G.
Differential signaling via surface IgM is associated with VH gene mutational
status and CD38 expression in chronic lymphocytic leukemia. Blood. (2003)
101:1087–93. doi: 10.1182/blood-2002-06-1822
14. Scielzo C, Camporeale A, Geuna M, Alessio M, Poggi A, Zocchi
MR, et al. ZAP-70 is expressed by normal and malignant human B-
cell subsets of different maturational stage. Leukemia. (2006) 20:689–95.
doi: 10.1038/sj.leu.2404138
15. Wandroo F, Bell A, Darbyshire P, Pratt G, Stankovic T, Gordon J,
et al. ZAP-70 is highly expressed in most cases of childhood pre-B
cell acute lymphoblastic leukemia. Int J Lab Hematol. (2008) 30:149–57.
doi: 10.1111/j.1751-553X.2007.00915.x
16. Guillaume N, Alleaume C, Munfus D, Capiod JC, Touati G, Pautard B,
et al. ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated
in B-lineage acute lymphoblastic leukemia cells. Haematologica. (2005)
90:899–905. Available online at: https://www.haematologica.org/article/view/
3587
17. Chakupurakal G, Bell A, Griffiths M, Wandroo F, Moss P. Analysis of ZAP70
expression in adult acute lymphoblastic leukaemia by real time quantitative
PCR.Mol Cytogenet. (2012) 5:22. doi: 10.1186/1755-8166-5-22
18. Sup SJ, Domiati-Saad R, Kelley TW, Steinle R, Zhao X, Hsi ED. ZAP-70
expression in B-cell hematologic malignancy is not limited to CLL/SLL. Am
J Clin Pathol. (2004) 122:582–7. doi: 10.1309/WVQPVDF8UF7AV21X
19. Schweighoffer E, Vanes L, Mathiot A, Nakamura T, Tybulewicz VL.
Unexpected requirement for ZAP-70 in pre-B cell development
and allelic exclusion. Immunity. (2003) 18:523–33. doi: 10.1016/
S1074-7613(03)00082-7
20. Fallah-Arani F, Schweighoffer E, Vanes L, Tybulewicz VL. Redundant role
for Zap70 in B cell development and activation. Eur J Immunol. (2008)
38:1721–33. doi: 10.1002/eji.200738026
21. Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE, Jelinek DF. ZAP-
70 is expressed by a subset of normal human B-lymphocytes displaying
an activated phenotype. Leukemia. (2005) 19:1018–24. doi: 10.1038/sj.leu.
2403726
22. Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K,
et al. Validation of ZAP-70 methylation and its relative significance in
predicting outcome in chronic lymphocytic leukemia. Blood. (2014) 124:42–8.
doi: 10.1182/blood-2014-02-555722
23. Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M,
et al. Quantitative DNA methylation analysis identifies a single CpG
dinucleotide important for ZAP-70 expression and predictive of prognosis
in chronic lymphocytic leukemia. J Clin Oncol. (2012) 30:2483–91.
doi: 10.1200/JCO.2011.39.3090
24. Corcoran M, Parker A, Orchard J, Davis Z, Wirtz M, Schmitz OJ, et al. ZAP-
70 methylation status is associated with ZAP-70 expression status in chronic
lymphocytic leukemia.Haematologica. (2005) 90:1078–88. Available online at:
https://haematologica.org/article/view/3628
25. Bekeredjian-Ding I, Doster A, Schiller M, Heyder P, Lorenz HM,
Schraven B, et al. TLR9-activating DNA up-regulates ZAP70 via sustained
PKB induction in IgM+ B cells. J Immunol. (2008) 181:8267–77.
doi: 10.4049/jimmunol.181.12.8267
26. Wagner M, Oelsner M, Moore A, Gotte F, Kuhn PH, Haferlach T,
et al. Integration of innate into adaptive immune responses in ZAP-
70-positive chronic lymphocytic leukemia. Blood. (2016) 127:436–48.
doi: 10.1182/blood-2015-05-646935
27. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, et al. ZAP-
70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood.
(2005) 105:2036–41. doi: 10.1182/blood-2004-05-1715
28. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP-70
enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase
activation in chronic lymphocytic leukemia and lymphoma B cells. Blood.
(2007) 109:2032–9. doi: 10.1182/blood-2006-03-011759
29. Chen L, Huynh L, Apgar J, Tang L, Rassenti L,Weiss A, et al. ZAP-70 enhances
IgM signaling independent of its kinase activity in chronic lymphocytic
leukemia. Blood. (2008) 111:2685–92. doi: 10.1182/blood-2006-12-062265
30. McHeik S, Van Eeckhout N, De Poorter C, Gales C, Parmentier M, Springael
JY. Coexpression of CCR7 and CXCR4 during B cell development controls
CXCR4 responsiveness and bone marrow homing. Front Immunol. (2019)
10:2970. doi: 10.3389/fimmu.2019.02970
31. Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, et al.
Expression of the chemokine receptors CXCR4 and CCR7 and disease
progression in B-cell chronic lymphocytic leukemia/small lymphocytic
lymphoma.Mayo Clin Proc. (2004) 79:318–25. doi: 10.4065/79.3.318
32. Du H, Zhang L, Li G, Liu W, Tang W, Zhang H, et al. CXCR4
and CCR7 expression in primary nodal diffuse large B-cell lymphoma-A
clinical and immunohistochemical study. Am J Med Sci. (2019) 357:302–10.
doi: 10.1016/j.amjms.2019.01.008
33. Hauser MA, Schaeuble K, Kindinger I, Impellizzieri D, Krueger WA, Hauck
CR, et al. Inflammation-induced CCR7 oligomers form scaffolds to integrate
distinct signaling pathways for efficient cell migration. Immunity. (2016)
44:59–72. doi: 10.1016/j.immuni.2015.12.010
34. Calpe E, Codony C, Baptista MJ, Abrisqueta P, Carpio C, Purroy N, et al.
ZAP-70 enhances migration of malignant B lymphocytes toward CCL21
by inducing CCR7 expression via IgM-ERK1/2 activation. Blood. (2011)
118:4401–10. doi: 10.1182/blood-2011-01-333682
35. Richardson SJ, Matthews C, Catherwood MA, Alexander HD,
Carey BS, Farrugia J, et al. ZAP-70 expression is associated with
enhanced ability to respond to migratory and survival signals in B-
cell chronic lymphocytic leukemia (B-CLL). Blood. (2006) 107:3584–92.
doi: 10.1182/blood-2005-04-1718
36. Laufer JM, Lyck R, Legler DF. ZAP70 expression enhances chemokine-driven
chronic lymphocytic leukemia cell migration and arrest by valency regulation
of integrins. FASEB J. (2018) 32:4824–35. doi: 10.1096/fj.201701452RR
37. Alsadeq A, Fedders H, Vokuhl C, Belau NM, Zimmermann M, Wirbelauer
T, et al. The role of ZAP70 kinase in acute lymphoblastic leukemia
infiltration into the central nervous system. Haematologica. (2017) 102:346–
55. doi: 10.3324/haematol.2016.147744
38. Arvaniti E, Ntoufa S, Papakonstantinou N, Touloumenidou T, Laoutaris
N, Anagnostopoulos A, et al. Toll-like receptor signaling pathway in
chronic lymphocytic leukemia: distinct gene expression profiles of potential
pathogenic significance in specific subsets of patients. Haematologica. (2011)
96:1644–52. doi: 10.3324/haematol.2011.044792
39. Decker T, Schneller F, Kronschnabl M, Dechow T, Lipford GB, Wagner
H, et al. Immunostimulatory CpG-oligonucleotides induce functional high
affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results
in a highly immunogenic phenotype. Exp Hematol. (2000) 28:558–68.
doi: 10.1016/S0301-472X(00)00144-2
40. Correia RP, Matos ESFA, Bacal NS, Campregher PV, Hamerschlak N,
Amarante-Mendes GP. ZAP-70 expression is associated with increased
Frontiers in Oncology | www.frontiersin.org 7 October 2020 | Volume 10 | Article 595832
Chen et al. Immune-Regulation Through ZAP-70
CD4 central memory T cells in chronic lymphocytic leukemia:
cross-sectional study. Hematol Transfus Cell Ther. (2018) 40:317–25.
doi: 10.1016/j.htct.2018.03.008
41. Grywalska E, Bartkowiak-Emeryk M, Pasiarski M, Olszewska-Bozek K,
Mielnik M, Podgajna M, et al. Relationship between the expression of CD25
and CD69 on the surface of lymphocytes T and B from peripheral blood and
bone marrow of patients with chronic lymphocytic leukemia and established
prognostic factors of this disease. Adv Clin Exp Med. (2018) 27:987–99.
doi: 10.17219/acem/74437
42. Rivkina A, Holodnuka-Kholodyuk I, Murovska M, Soloveichika M, Lejniece
S. Peripheral blood lymphocyte phenotype of ZAP-70(+) and ZAP-70(-)
patients with B-cell chronic lymphocytic leukaemia. Exp Oncol. (2015) 37:73–
6. doi: 10.31768/2312-8852.2015.37(1):73-76
43. Burger JA, QuirogaMP, Hartmann E, Burkle A,WierdaWG, KeatingMJ, et al.
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic
lymphocytic leukemia B cells in nurselike cell cocultures and after BCR
stimulation. Blood. (2009) 113:3050–8. doi: 10.1182/blood-2008-07-170415
44. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, et al.
CCL3 (MIP-1alpha) plasma levels and the risk for disease progression
in chronic lymphocytic leukemia. Blood. (2011) 117:1662–9. doi: 10.1182/
blood-2010-09-307249
45. Kansara RR, Speziali C. Immunotherapy in hematologic malignancies. Curr
Oncol. (2020) 27:S124–31. doi: 10.3747/co.27.5117
46. Elder ME, Lin D, Clever J, Chan AC, Hope TJ, Weiss A, et al. Human severe
combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine
kinase. Science. (1994) 264:1596–9. doi: 10.1126/science.8202712
47. Chan AY, Punwani D, Kadlecek TA, Cowan MJ, Olson JL, Mathes EF, et al.
A novel human autoimmune syndrome caused by combined hypomorphic
and activating mutations in ZAP-70. J Exp Med. (2016) 213:155–65.
doi: 10.1084/jem.20150888
48. Jenkins MR, Stinchcombe JC, Au-Yeung BB, Asano Y, Ritter AT, Weiss
A, et al. Distinct structural and catalytic roles for Zap70 in formation of
the immunological synapse in CTL. eLife. (2014) 3:e01310. doi: 10.7554/
eLife.01310.018
49. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on
the response of T cells to stimulation. J Exp Med. (1995) 182:459–65.
doi: 10.1084/jem.182.2.459
50. Guntermann C, Alexander DR. CTLA-4 suppresses proximal TCR signaling
in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319)
phosphorylation: a potential role for tyrosine phosphatases. J Immunol. (2002)
168:4420–9. doi: 10.4049/jimmunol.168.9.4420
51. Thaker YR, Raab M, Strebhardt K, Rudd CE. GTPase-activating protein
Rasal1 associates with ZAP-70 of the TCR and negatively regulates
T-cell tumor immunity. Nat Commun. (2019) 10:4804. doi: 10.1038/
s41467-019-12544-4
52. Newell A, Dadi H, Goldberg R, Ngan BY, Grunebaum E, Roifman CM. Diffuse
large B-cell lymphoma as presenting feature of Zap-70 deficiency. J Allergy
Clin Immunol. (2011) 127:517–20. doi: 10.1016/j.jaci.2010.09.016
53. Childs RW, Carlsten M. Therapeutic approaches to enhance natural killer cell
cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov. (2015)
14:487–98. doi: 10.1038/nrd4506
54. Chiesa S, Mingueneau M, Fuseri N, Malissen B, Raulet DH, Malissen M,
et al. Multiplicity and plasticity of natural killer cell signaling pathways. Blood.
(2006) 107:2364–72. doi: 10.1182/blood-2005-08-3504
55. Pugh JL, Nemat-Gorgani N, Norman PJ, Guethlein LA, Parham P. HumanNK
cells downregulate Zap70 and syk in response to prolonged activation or DNA
damage. J Immunol. (2018) 200:1146–58. doi: 10.4049/jimmunol.1700542
56. Hideshima T, Ogiya D, Liu J, Harada T, Kurata K, Bae J, et al.
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-
dependent pathways. Leukemia. (2020). doi: 10.1038/s41375-020-0809-x.
[Epub ahead of print].
57. Zompi S, Hamerman JA, Ogasawara K, Schweighoffer E, Tybulewicz VL,
Di Santo JP, et al. NKG2D triggers cytotoxicity in mouse NK cells lacking
DAP12 or Syk family kinases. Nat Immunol. (2003) 4:565–72. doi: 10.1038/
ni930
58. Colucci F, Schweighoffer E, Tomasello E, Turner M, Ortaldo JR, Vivier E, et al.
Natural cytotoxicity uncoupled from the Syk and ZAP-70 intracellular kinases.
Nat Immunol. (2002) 3:288–94. doi: 10.1038/ni764
59. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric
antigen receptor design. Cancer Discov. (2013) 3:388–98. doi: 10.1158/
2159-8290.CD-12-0548
60. Halim L, Maher J. CAR T-cell immunotherapy of B-cell malignancy: the
story so far. Ther Adv Vaccines Immunother. (2020) 8:2515135520927164.
doi: 10.1177/2515135520927164
61. Karlsson H, Svensson E, Gigg C, Jarvius M, Olsson-Stromberg U, Savoldo
B, et al. Evaluation of intracellular signaling downstream chimeric antigen
receptors. PLoS ONE. (2015) 10:e0144787. doi: 10.1371/journal.pone.0144787
62. Gudipati V, Rydzek J, Doel-Perez I, Goncalves VDR, Scharf L, Konigsberger
S, et al. Inefficient CAR-proximal signaling blunts antigen sensitivity. Nat
Immunol. (2020) 21:848–56. doi: 10.1038/s41590-020-0719-0
63. Kaur M, Singh M, Silakari O. Insight into the therapeutic aspects of ’Zeta-
Chain associated protein kinase 70 kDa’ inhibitors: a review.Cell Signal. (2014)
26:2481–92. doi: 10.1016/j.cellsig.2014.06.017
64. Au-Yeung BB, Levin SE, Zhang C, Hsu LY, Cheng DA, Killeen N, et al. A
genetically selective inhibitor demonstrates a function for the kinase Zap70
in regulatory T cells independent of its catalytic activity. Nat Immunol. (2010)
11:1085–92. doi: 10.1038/ni.1955
65. Nishikawa K, Sawasdikosol S, Fruman DA, Lai J, Songyang Z, Burakoff
SJ, et al. A peptide library approach identifies a specific inhibitor
for the ZAP-70 protein tyrosine kinase. Mol Cell. (2000) 6:969–74.
doi: 10.1016/S1097-2765(05)00085-7
66. Visperas PR, Wilson CG, Winger JA, Yan Q, Lin K, Arkin MR, et al.
Identification of inhibitors of the association of ZAP-70 with the T cell
receptor by high-throughput screen. SLAS Discov Adv Life Sci R D. (2017)
22:324–31. doi: 10.1177/1087057116681407
67. Dielschneider RF, Xiao W, Yoon JY, Noh E, Banerji V, Li H, et al.
Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells
and inhibits B-cell receptor signaling. Cell Death Dis. (2014) 5:e1439.
doi: 10.1038/cddis.2014.391
68. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke
FL, et al. Chimeric antigen receptor T-cell therapy - assessment and
management of toxicities. Nat Rev Clin Oncol. (2018) 15:47–62. doi: 10.1038/
nrclinonc.2017.148
69. Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T,
et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic
on/off switch for CAR T cells. Sci Translat Med. (2019) 11:eaau5907.
doi: 10.1126/scitranslmed.aau5907
70. Levin SE, Zhang C, Kadlecek TA, Shokat KM, Weiss A. Inhibition of ZAP-
70 kinase activity via an analog-sensitive allele blocks T cell receptor and
CD28 superagonist signaling. J Biol Chem. (2008) 283:15419–30. doi: 10.1074/
jbc.M709000200
71. Wong NML, Wong WW. Engineering a dual small molecule gated
ZAP70 switch in T cells. ACS Synth Biol. (2018) 7:969–77. doi: 10.1021/
acssynbio.7b00394
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Chen, Moore and Ringshausen. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Oncology | www.frontiersin.org 8 October 2020 | Volume 10 | Article 595832
